Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11ClN2O4S |
| Molecular Weight | 278.713 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
InChI
InChIKey=KXSAIQPPGSSNKX-ZETCQYMHSA-N
InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
| Molecular Formula | C9H11ClN2O4S |
| Molecular Weight | 278.713 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:14:41 GMT 2023
by
admin
on
Sat Dec 16 05:14:41 GMT 2023
|
| Record UNII |
G1TI012DLT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11616111
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
871824-55-4
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
JNJ-26489112
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. JNJ-26489112 is also being studied as a treatment for major depressive disorder. | ||
|
DB15203
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
DTXSID601031470
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY | |||
|
G1TI012DLT
Created by
admin on Sat Dec 16 05:14:41 GMT 2023 , Edited by admin on Sat Dec 16 05:14:41 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Developer: Janssen Research & Development; Class: Antidepressant, Antiepileptic drug; Highest Development Phase: Discontinued for Epilepsy, Major depressive disorder; Most Recent Events: 01 Oct 2013 Discontinued - Phase-I for Epilepsy (in volunteers) in Belgium (PO), 01 Oct 2013 Discontinued - Phase-II for Epilepsy in USA (PO), 12 Mar 2012 Discontinued - Phase-II for Depressive disorders in USA (PO)
|
||
|
ACTIVE MOIETY |
RESULTS: The majority of patients showed a positive response on day 2 following JNJ-26489112 administration: 3/4 patients (1000 mg dose), 3/4 patients (2000 mg dose), and 2/3 patients (3000 mg). There was an apparent dose-dependent effect observed in patients who exhibited complete suppression of the SPR: 0/4 patients (1000 mg dose), 1/4 patient (2000 mg dose), and 2/3 patients (3000 mg dose). The median tmax of JNJ-26489112 (range: 3.73-5.04 h) in plasma was similar across all 3 dose groups and plasma exposure of JNJ-26489112 increased proportionally with dose approximate mean Cmax of 16, 28, and 42 .MU.g/mL for the 1000-, 2000-, and 3000 mg cohorts, respectively. Concentrations of other AEDs did not appear to be affected by co-administration of JNJ-26489112. JNJ-26489112 was generally well-tolerated with the most frequent adverse events (>10%) reported being mild headache, dizziness, and nausea.
|
